Hariri, AmiraliKhosravı, ArezooMirian, MinaKhosravi, ArezooZarepour, AtefehIravani, SiavashZarrabi, AliGenetik ve Biyomühendislik / Genetic and Bio-Engineering2024-09-112024-09-11202401368-76461532-208410.1016/j.drup.2024.1011192-s2.0-85200320134https://doi.org/10.1016/j.drup.2024.101119https://hdl.handle.net/20.500.14517/6213Cancer metastasis and therapy resistance are intricately linked with the dynamics of Epithelial-Mesenchymal Transition (EMT) and Circulating Tumor Cells (CTCs). EMT hybrid cells, characterized by a blend of epithelial and mesenchymal traits, have emerged as pivotal in metastasis and demonstrate remarkable plasticity, enabling transitions across cellular states crucial for intravasation, survival in circulation, and extravasation at distal sites. Concurrently, CTCs, which are detached from primary tumors and travel through the bloodstream, are crucial as potential biomarkers for cancer prognosis and therapeutic response. There is a significant interplay between EMT hybrid cells and CTCs, revealing a complex, bidirectional relationship that significantly influences metastatic progression and has a critical role in cancer drug resistance. This resistance is further influenced by the tumor microenvironment, with factors such as tumor-associated macrophages, cancer-associated fibroblasts, and hypoxic conditions driving EMT and contributing to therapeutic resistance. It is important to understand the molecular mechanisms of EMT, characteristics of EMT hybrid cells and CTCs, and their roles in both metastasis and drug resistance. This comprehensive understanding sheds light on the complexities of cancer metastasis and opens avenues for novel diagnostic approaches and targeted therapies and has significant advancements in combating cancer metastasis and overcoming drug resistance.eninfo:eu-repo/semantics/closedAccessDrug resistanceCancer metastasisCircular tumor cellsEpithelial-mesenchymal transitionArticleQ1Q176WOS:00129097730000139111134